The purpose of this study is to evaluate the efficacy of Cipros 20 association in the treatment of dyslipidemia treatment.

Inclusion Criteria:

• Participants of both sexes, aged 18 years or more;
• Participants with the diagnosed of dyslipidemia and with high or very high cardiovascular risk, according to the Brazillian Guidelines on Dyslipidemia and Prevention of Atherosclerosis;
• Signed consent.

Exclusion Criteria:

• Using medications that may interfere with the metabolism or serum levels of triglycerides;
• Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
• Presence of concomitant cardiovascular disease, renal failure and hepatic failure;
• Decompensated diabetes;
• Current smoking;
• History hypersensitivity to the active ingredients used in the study;
• Pregnancy or risk of pregnancy and lactating patients;
• History of alcohol abuse or illicit drug use;
• Participation in clinical trial in the year prior to this study.